Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries
about
Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database studyReal-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes.Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2.Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice.Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
P2860
Q33732593-CF3BA862-566C-4B0B-8A77-9870EFA644FBQ33797431-357719B6-C431-406B-925C-8936E682FCC4Q37114961-16C350DE-41D5-4911-AD90-853C49814163Q37418019-B9D9A424-70DE-489E-AA90-9DD0EF04D99FQ37639302-D76FAF23-A688-4F47-8062-B5A8E85FCE07Q37639316-F440BF4E-70C0-4413-911B-EDFCA66F2CC2Q37737470-F5109D6C-D575-406C-BE0F-899453478B3BQ38765656-FAD9EF27-2CE5-4455-9915-65A66DB7C9A1Q39069417-A37B2061-7382-4292-853F-DC91EDDB0BB9Q39489506-A9A12E76-A60A-4EF7-91EA-A90E2F78DB73Q42371337-EDB43D66-7AA2-46FB-8D4C-BCCB1D79BEEFQ47602613-43EFC0C6-0135-4073-A35B-725B383B9471Q48228283-5AFDF2CF-E7E0-4287-BAD9-395470EE1275Q52662396-BDF026B4-C861-4AB6-945A-5BE37F7C6223
P2860
Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Glucagon-like Peptide-1 recept ...... ents in six European countries
@ast
Glucagon-like Peptide-1 recept ...... ents in six European countries
@en
Glucagon-like Peptide-1 recept ...... ents in six European countries
@nl
type
label
Glucagon-like Peptide-1 recept ...... ents in six European countries
@ast
Glucagon-like Peptide-1 recept ...... ents in six European countries
@en
Glucagon-like Peptide-1 recept ...... ents in six European countries
@nl
prefLabel
Glucagon-like Peptide-1 recept ...... ents in six European countries
@ast
Glucagon-like Peptide-1 recept ...... ents in six European countries
@en
Glucagon-like Peptide-1 recept ...... ents in six European countries
@nl
P2093
P2860
P1433
P1476
Glucagon-like Peptide-1 recept ...... ents in six European countries
@en
P2093
Matthew Reaney
Mitch DeKoven
Nebibe Varol
Sara Bruce Wirta
Shawn Hallinan
Victoria Divino
Won Chan Lee
P2860
P2888
P304
P356
10.1007/S13300-014-0087-6
P577
2014-11-04T00:00:00Z
P5875
P6179
1006217620